FocalTherics (FOCL)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

FocalTherics (FOCL) is up 48.9% since the beginning of the year. At $5 per share, FOCL is trading just below its 52-week high of $5. Investors who bought $1,000 worth of FOCL shares 5 years ago would now be looking at an investment worth $695.

FocalTherics (FOCL) has returned 48.94% so far this year and 188.57% over the past 12 months. Over the last ten years, FOCL has returned 4.86% per year, falling short of the S&P 500 Index benchmark, which averaged 13.71% annually.

Based on dividend-adjusted daily data since Aug 1, 1997, FOCL's average daily return is +0.15%, while the average monthly return is +1.93%. At this rate, an investment would double in approximately 3.0 years.

Historically, 44% of months were positive and 56% were negative. The best month was Aug 2009 with a return of +171.2%, while the worst month was Jul 2014 at -61.5%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 9 months.

On a daily basis, FOCL closed higher 43% of trading days. The best single day was Aug 19, 2009 with a return of +206.6%, while the worst single day was Jul 31, 2014 at -43.9%.

FocalTherics has an annualized alpha of 39.69%, beta of 0.48, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since August 01, 1997.

• This stock participated in 105.78% of S&P 500 Index downside but only 63.02% of its upside - more exposed to losses than it benefited from rallies.
• Beta of 0.48 may look defensive, but with R2 of 0.01 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

FOCL ranks 90 for risk / return — in the top 90% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the FocalTherics. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the FocalTherics was 95.38%, occurring on Apr 21, 2009. The portfolio has not yet recovered.

The current FocalTherics drawdown is 76.41%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of FocalTherics over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how FocalTherics is priced in the market compared to other companies in the Medical Devices industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.